OPINION
Published on 04 Jan 2023
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
doi 10.3389/fonc.2022.1098375
- 8,880 views
- 1 citation
- Frontiers in Oncology
- Hematologic Malignancies
- Research Topics
- Point and Counterpoint - The Trainees' Corner
Point and Counterpoint - The Trainees' Corner
3,597
Total downloads
15k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
OPINION
Published on 08 Sep 2021
Debating Frontline Therapy in Chronic Myeloid Leukemia
doi 10.3389/fonc.2021.708823
- 2,237 views
- 1 citation
OPINION
Published on 04 Jun 2021
Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?
doi 10.3389/fonc.2021.686223
- 6,491 views
- 1 citation
OPINION
Published on 22 Dec 2020
Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond
doi 10.3389/fonc.2020.562219
- 4,462 views
- 6 citations
OPINION
Published on 22 Oct 2020
Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
doi 10.3389/fonc.2020.576924
- 2,183 views
- 2 citations
Published in
Frontiers in Oncology
- Hematologic Malignancies
Impact
- 15kTopic views
- 11kArticle views
- 3,597Article downloads